Travere Therapeutics (TVTX) Receivables (2014 - 2026)
Travere Therapeutics' (TVTX) quarterly Receivables came in at $88.5 million in Q1 2026, up 142.47% YoY from $36.5 million in Q1 2025, and up 8.72% on a QoQ basis from $81.4 million in Q4 2025.
Travere Therapeutics (TVTX) Receivables (2014 - 2026) Analysis & Trends
Travere Therapeutics (TVTX) has 13 years of Receivables data on file, last reported at $88.5 million in Q1 2026.
- Quarterly Receivables rose 142.47% year-over-year to $88.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $88.5 million (up 142.47% YoY) and the FY2025 annual result came in at $81.4 million, up 176.84% from the prior year.
- Receivables grew to $88.5 million in Q1 2026, from $81.4 million in the prior quarter.
- In the past five years, Receivables ranged from a high of $88.5 million in Q1 2026 to a low of $12.7 million in Q3 2022.
- A 5-year average of $35.0 million and a median of $26.5 million in 2024 frame the typical range for Receivables.
- Annual changes were most pronounced in 2022 — Receivables declined 5.22% — and 2025, when it surged 205.05%.
- Tracing TVTX's Receivables over 5 years: stood at $18.5 million in 2022, then soared by 39.0% to $25.8 million in 2023, then gained by 14.11% to $29.4 million in 2024, then surged by 176.72% to $81.4 million in 2025, then increased by 8.72% to $88.5 million in 2026.
- The last three Receivables figures came in at $88.5 million (Q1 2026), $81.4 million (Q4 2025), and $84.5 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 2.13 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 6.57 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.93 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.06 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 1.84 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 912.74 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 215.33 Mn |
| 10 | Travere Therapeutics | 5.85 Bn | 5.85 Bn | 162.52 Mn | 82.94 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 82.94 Mn |
| Mar 31, 2026 | 88.50 Mn |
| Dec 31, 2025 | 81.40 Mn |
| Sep 30, 2025 | 84.50 Mn |
| Jun 30, 2025 | 40.22 Mn |
| Mar 31, 2025 | 36.50 Mn |
| Dec 31, 2024 | 29.42 Mn |
| Sep 30, 2024 | 27.70 Mn |
| Jun 30, 2024 | 27.27 Mn |
| Mar 31, 2024 | 26.53 Mn |
| Dec 31, 2023 | 25.78 Mn |
| Sep 30, 2023 | 18.70 Mn |
| Jun 30, 2023 | 22.90 Mn |
| Mar 31, 2023 | 23.54 Mn |
| Dec 31, 2022 | 18.55 Mn |
| Sep 30, 2022 | 12.70 Mn |
| Jun 30, 2022 | 16.69 Mn |
| Mar 31, 2022 | 14.70 Mn |
| Dec 31, 2021 | 16.81 Mn |
| Sep 30, 2021 | 13.40 Mn |